We are live on ! Find out more
GRCE

Grace Therapeutics

16 hedge funds and large institutions have $6.71M invested in Grace Therapeutics in 2014 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more capital invested

Capital invested by funds: $4.63M → $6.71M (+$2.08M)

33% more funds holding

Funds holding: 1216 (+4)

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
16
Holders Change
+4
Holders Change %
+33.33%
% of All Funds
0.46%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
1
Reduced
6
Closed
Calls
Puts
Net Calls
Net Calls Change

GRCE Hedge Fund Activity: Q2 2014 in Review

16 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q2 2014, worth a combined $6.71M — up 45% from $4.63M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new GRCE positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 6 trimmed.

The largest buyer was Fiera Capital (Canada), opening a new position worth an estimated $1.61M. The largest seller was Perceptive Advisors, cutting an estimated $301K.

  • 16 institutional investors held Grace Therapeutics (GRCE) as of Q2 2014, up from 12 in Q1 2014.
  • Funds reported $6.71M of Grace Therapeutics stock for Q2 2014, up 45% quarter-over-quarter.
  • 4 funds opened new Grace Therapeutics positions in Q2 2014 and 0 closed out, a net change of +4 holders.
  • The largest Grace Therapeutics buyer in Q2 2014 was Fiera Capital (Canada), an estimated $1.61M added.
  • The largest Grace Therapeutics seller in Q2 2014 was Perceptive Advisors, an estimated $301K sold.

Based on aggregated 13F filings for Q2 2014.